Name
Industry Expert Session IX (Non-Accredited): Dessert
Date & Time
Friday, September 5, 2025, 7:46 PM - 8:46 PM
Description
MONJUVI + Rituximab & Lenalidomide: The First and Only CD19- and CD20-targeted Immunotherapy Combination Approved for 2L+ Follicular Lymphoma Patients
M. Yair Levy, MD | Baylor University Medical Center | Dallas, Texas, USA
This activity is sponsored by Incyte
Location Name
GRB Level 3, GRAND BALLROOM C, THEATER 2
Session Document 1
Session Document 2
Download Document 1
Virtual Session Link